newsfilter
← Latest News
GlobeNewswire·

Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial ("SKYLINE"), completing proof-of-concept for all three monotherapies in inflammatory bowel disease ("IBD").